United States

Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)

Advised the Ad Hoc Group of First-Lien Term Loan lenders of Ascena Retail Group, Inc. with respect to (i) negotiation of a restructuring support agreement, including a fully backstopped DIP and exit financing and (ii) a sale of Ann Taylor, LOFT and Lane Bryant as well as the intellectual property assets of the Justice and Catherine’s brands.

Advising Northern Data AG, a Germany based developer and operator of high-performance computing (“HPC”) infrastructure solutions, on the sale of its U.S. subsidiary Whinstone Inc., an HPC data center operator based in Rockdale, Texas, to Riot Blockchain Inc., a U.S. based publicly-traded bitcoin miner

Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Skillsoft Limited, a leading provider of e-learning and performance support solutions globally

Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"

Advising Genesis Park Acquisition Corp., a special purpose acquisition company (SPAC) focused on aviation and related end markets, on the acquisition of Redwire, LLC, a pure play leading developer of mission critical solutions for next generation space infrastructure and a portfolio company of AE Industrial Partners, LP 

Advised Canopy Growth, a leading diversified cannabis company, on its US$750 million term loan financing with King Street Capital Management, L.P.

Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio

Advising Net Insight AB, a global leader in media networks, on the divestment of its resource optimization software business area, doing business as “ScheduALL” to Xytech Systems Corporation

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share